FDA says Vertex hepatitis drug is highly effective

Apr 26, 2011

(AP) -- Federal health officials say a highly anticipated hepatitis C drug from Vertex Pharmaceuticals successfully treats a clear majority of patients in less time than older medicines that have been used for 20 years.

The posted its review of Vertex's telaprevir ahead of a meeting Thursday where outside experts will vote on the benefits of the drug. On Wednesday the experts will review a similar drug from Merck.

Both new drugs work by blocking the enzyme protease, which allows the hepatitis virus to reproduce. The new approach represents a breakthrough from older medicines, which are designed to help the fight hepatitis.

FDA scientists said 79 percent of patients who added telaprevir to older medicines were virus free six months after treatment.

Explore further: FDA approves hard-to-abuse narcotic painkiller

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA says Merck drug successfully fights hepatitis

Apr 25, 2011

Federal health officials said Monday a highly-anticipated drug to treat hepatitis C made by Merck appears to cure more patients in less time than established drugs that have been used for 20 years. But the agency has questions ...

New treatment for hepatitis C

May 14, 2008

Researchers at the University of Oklahoma Health Sciences Center have found a new use for an old drug. Their findings appear online in the American Journal of Gastroenterology.

New hope for hepatitis C, an often hidden disease

Jan 17, 2011

There's new hope for an overlooked epidemic: Two powerful drugs are nearing the market that promise to help cure many more people of liver-attacking hepatitis C - even though most who have the simmering infection ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

neiorah
not rated yet Apr 26, 2011
Great, now the need for liver transplants will go down